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Abstract
Mutations in genes encoding proteins involved in RNA splicing have been found to occur at relatively high
frequencies in several tumour types including myelodysplastic syndromes, chronic lymphocytic leukaemia, uveal
melanoma, and pancreatic cancer, and at lower frequencies in breast cancer. To investigate whether dysfunction in
RNA splicing is implicated in the pathogenesis of breast cancer, we performed a re-analysis of published exome and
whole genome sequencing data. This analysis revealed that mutations in spliceosomal component genes occurred
in 5.6% of unselected breast cancers, including hotspot mutations in the SF3B1 gene, which were found in
1.8% of unselected breast cancers. SF3B1 mutations were significantly associated with ER-positive disease, AKT1
mutations, and distinct copy number alterations. Additional profiling of hotspot mutations in a panel of special
histological subtypes of breast cancer showed that 16% and 6% of papillary and mucinous carcinomas of the
breast harboured the SF3B1 K700E mutation. RNA sequencing identified differentially spliced events expressed in
tumours with SF3B1 mutations including the protein coding genes TMEM14C, RPL31, DYNL11, UQCC, and ABCC5,
and the long non-coding RNA CRNDE. Moreover, SF3B1 mutant cell lines were found to be sensitive to the SF3b
complex inhibitor spliceostatin A and treatment resulted in perturbation of the splicing signature. Albeit rare,
SF3B1 mutations result in alternative splicing events, and may constitute drivers and a novel therapeutic target
in a subset of breast cancers.
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
The ability to characterize entire genomes at base
pair resolution using massively parallel sequencing
technologies provides a unique opportunity to unravel
genotypic–phenotypic associations in breast cancer,
which can be exploited for the identification of drivers
of tumourigenesis and, ultimately, therapeutic targets.
Recent breast cancer sequencing studies have high-
lighted the complex nature of the landscape of breast
cancer genomes, characterizing both the mutational
signatures of breast cancer [1–3] and their mutational
repertoire [4–8]. These seminal studies have high-
lighted that there are a few highly recurrent mutations
in breast cancer, including TP53 and PIK3CA, and
a wide spectrum of genes mutated in a small minor-
ity of tumours. However, some of the low-frequency
mutations (i.e. present in 0.5–2%) of breast cancers
constitute bona fide drivers and therapeutic targets in
other cancer types, such as BRAF and KRAS activating
hotspot mutations [6].
In addition to known drivers, massively parallel
sequencing studies have resulted in the identification
of novel mutations in multiple components of the
RNA splicing machinery. Somatic mutations affecting
different spliceosomal component genes are preferen-
tially found in myeloid neoplasms showing features
of myelodysplasia (MDS) and seemingly occur in a
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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mutually exclusive manner [9]. In fact, mutations in
the splicing factor 3B subunit 1 gene (SF3B1) are
rather prevalent in MDS and found to be associated
with a distinct phenotype (i.e. the presence of ring
sideroblasts) and favourable clinical outcome [10,11].
Mutations in other splicing genes, such as the U2 small
nuclear RNA auxiliary factor 1 gene (U2AF1), the
serine/arginine-rich splicing factor 2 gene (SRSF2), and
the U2 small nuclear ribonucleoprotein auxiliary factor
35 kDa subunit-related protein 2 gene (ZRSR2), have
also been reported; however, these are less frequent and
not associated with ring sideroblasts in MDS patients
[9,10]. More recently, studies have identified mutations
in SF3B1 in subsets of solid tumours from multiple
anatomic sites (see ref 11 for a recent review), including
15% of chronic lymphocytic leukaemias (CLLs) [12],
9.7% of uveal melanomas [13], 4% of pancreatic can-
cers [14], and 1.8% of breast cancers [4–6,8]. Although
these mutations have been shown to result in phenotypic
changes exemplified by their impact on RNA splicing
events in CLLs and uveal melanomas, their impact on
outcome seems to vary according to tumour type.Whilst
in patients with CLL these mutations are associated
with a poor outcome, in patients with uveal melanoma,
SF3B1 mutations are reported to be associated with a
good prognosis [12,13,15,16].
Given that mutations affecting spliceosomal com-
ponent genes have been reported in multiple tumour
types, including breast cancer, and may constitute driver
events in a subset of cancers, we performed a systematic
re-analysis of publicly available exome, whole genome,
and RNA sequencing data available for breast cancers.
Our aims were to determine whether mutations affect-
ing spliceosomal component genes are associated with
specific breast cancer subtypes and, if present, whether
these mutations were associated with distinct splicing
events and would constitute targets for therapy in these
tumours.
Materials and methods
Re-analysis of publicly available whole genome
and exome massively parallel sequencing datasets
Exome and whole genome sequencing data for 1293
tumours were obtained from The Cancer Genome
Atlas (TCGA) and other published studies [3–8].
Processed variant calls reported in these studies were
annotated using the Ensembl Variant effect predic-
tor [17] and mutational gene frequencies computed.
Binary alignment mapping (BAM) files of SF3B1
mutant tumours available in TCGA were used to assess
the heterozygosity at the SF3B1 locus using ASCAT
[18].
Tumour samples
Representative frozen or formalin-fixed, paraffin-
embedded (FFPE) samples from 65 breast cancers
classified as papillary (n= 19), mucinous (n= 18), and
micropapillary (n= 28) carcinomas were retrieved from
the authors’ institutions and surveyed for the presence
of the SF3B1 K700E hotspot mutation (Supplemen-
tary Table 1). All cases were reviewed by at least two
pathologists (CM, AS, AV-S, and/ or JSR-F) prior to
their inclusion in this study. This study was approved by
the authors’ local research ethics committees. Analyses
were performed anonymously.
Immunohistochemistry
Representative sections of each case were cut at 3 μm
and mounted on silane-coated slides. Immunohis-
tochemistry was performed as previously described
[19,20], using antibodies raised against oestrogen
receptor (ER), progesterone receptor (PR), HER2, and
epithelial membrane antigen (EMA). Antibody clones,
dilution, antigen retrieval methods, scoring systems,
and cut-offs are summarised in Supplementary Table
2. Positive and negative (omission of the primary anti-
body and IgG-matched serum) controls were included
for each immunohistochemical run. The scoring was
performed by at least two pathologists (CM, AS, AV-S,
and/ or JSR-F).
Nucleic acid extraction
DNA and/or RNA were extracted after gross dissection
of representative frozen or FFPE tissue blocks to ensure
that the samples contained more than 60% tumour cells
[21,22] (Supplementary methods). RNA quantity and
quality were assessed using the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA, USA).
Only samples with an RNA integrity number (RIN)
greater than 6 were used for RNA-sequencing library
construction.
Copy number analysis
Normalised circular binary segmented (cbs) SNP6 data
were retrieved from TCGA for available SF3B1 mutant
and wild-type tumours, matched on a 1 : 2 ratio for ER,
PR, HER2 status, and PIK3CA and TP53 mutational
status (Supplementary Table 3). SNP6 copy number
data were converted into categorical values by applying
thresholds as previously described and subjected to a
multi-Fisher exact test with adjustment for multiple
testing [23].
Targeted re-sequencing
Targeted DNA sequencing of ten recurrently mutated
genes identified in SF3B1mutated (n= 3) and wild-type
(n= 16) breast cancers was performed using the Ion
Torrent AmpliSeq technology according to the manu-
facturer’s instructions (Life Technologies, Paisley, UK)
(Supplementary methods and Supplementary Table 4).
Libraries were amplified using 10 ng of DNA per primer
pool using the IT AmpliSeq 2.0 kit and sequenced on
two 318 chips at a median depth of more than 1000. The
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 235: 571–580
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Torrent Suite v4.0.2 pipeline was used to align raw reads
and identify variants.
Paired-end massively parallel RNA sequencing
RNA sequencing was performed using 16 ng of
ribosomal-depleted RNA of 14 papillary carcino-
mas of the breast (three SF3B1 mutant and 11
SF3B1 wild-type) (Supplementary methods). Four
indexed samples were pooled at equimolar concen-
trations and sequenced on a single lane of a HiSeq
2500 using SBS v3 chemistry (Illumina, San Diego,
CA, USA) (2× 76 cycles). Samples were aligned to
the human genome (hg19 build 37) using TopHat
version 2.0.8b. Raw counts of reads mapped to
genes were calculated using HT-Seq (http://www-
huber.embl.de/users/anders/HTSeq/doc/overview.html)
and used as input for differential exon usage anal-
ysis using DEXSeq [24], with an adjusted p-value
cut-off of ≤0.1. FASTQ files from available TCGA
RNA-sequencing data from SF3B1 K700E mutant
(n= 8) and ER, PR, HER2 status, and PIK3CA and
TP53mutational status, and randomly matched controls
(n= 16) were downloaded from the Cancer Genomics
Hub (CGHub; https://cghub.ucsc.edu) and processed as
above (TCGA project access number 6223).
Raw targeted re-sequencing and RNA-sequencing
data have been deposited in the Sequence Read Archive
(SRA) (http://www.ncbi.nlm.nih.gov/sra) and are avail-
able under accession numbers PRJNA234087 and
PRJNA229096.
Reverse-transcription PCR (RT-PCR), PCR,
and Sanger sequencing validation
Reverse transcription was performed with Superscript
III (Invitrogen, Paisley, UK) using 50 ng of RNA per
reaction. SF3B1 K700E mutations were screened by
PCR and RT-PCR using KAPA Taq DNA Polymerase
(KAPA Biosystems, MA, USA) and sequenced as
previously described [22]. Sequences were visual-
ized using 4Peaks (http://4peaks.en.softonic.com/).
Primer sequences are listed in Supplementary
Table 5.
Splice variant analysis by quantitative PCR
Primers were designed against predicted alternatively
spliced exons using Primer 3 (http://primer3.ut.ee)
and retrieved from Furney et al [13] (Supplementary
Table 5). 1 ng of cDNA was analysed in duplicate
to quantify spliced and unspliced forms by real-time
quantitative PCR [13]. Briefly, 40 cycles of quantitative
reverse-transcription PCR (qRT-PCR) were conducted
in 384-well plates using Power SYBR Green reagents
(Invitrogen, Paisley, UK) on the ABI 9700HT. The
relative abundance of the spliced to unspliced form
was calculated using 2−(CT variant1 mRNA – CT variant2 mRNA).
For each splicing event, a two-tailed Mann–Whitney
U-test was applied between SF3B1 mutated (n= 3) and
wild-type (n= 11) cases.
Cell line models
Pancreatic Panc 05.04, PANC-1, Capan-1, Capan-2,
and endometrial cancer cell lines ESS-1, MFE296,
HEC1A, and HEC59 were obtained from ATCC (LGC
Standards, UK) and DSMZ (Braunschweig, Germany)
and maintained according to recommended growth con-
ditions. The identity of cell lines was confirmed by short
tandem repeat (STR) typing using the GenePrint 10 Kit
(Promega, UK). SF3B1mutant cell lines were identified
through COSMIC (http://cancer.sanger.ac.uk/cosmic)
and verified by means of Sanger sequencing using the
methods and primers described above.
Short interfering RNA (siRNA)-mediated silencing
SF3B1 plus eight genes that were consistently dif-
ferentially spliced in SF3B1 mutant versus wild-type
samples – namely ABCC5, ANKHD1, DYNLL1, F8,
RPL31, TMEM14C, UQCC, and CRNDE – were
selected for functional evaluation. Splice variant spe-
cific siRNAs were designed to differentially spliced
genes that showed large enough unique regions to
allow targeting of three or more independent oligos
(Supplementary Table 5). Cells were transfected with
target and control siRNAs in 96-well plates, using
Lipofectamine 2000 (Panc 05.04) or Lipofectamine
RNAiMax (Invitrogen). Cell viability was assessed 6–8
days post-transfection as previously described [25],
using the CellTiter-Glo® assay (Promega, UK). The
cell survival fraction for each siRNA was calculated
using the normalised percentage inhibition (NPI) as
previously described [26]. Validation of target gene
knockdown was performed using qRT-PCR using the
delta-delta CT method. Experiments were performed in
triplicate.
Drug sensitivity assays
Cell lines were plated in 96-well plates and 24 h
later, media were supplemented with serial dilutions
(10−5 –10−9 M) of spliceostatin A (SSA) (Bioquote,
York, UK). All experiments were performed in tripli-
cate. Survival was assessed with the CellTiter-Glo® cell
viability assay after 7 days of drug treatment. Survival
curves and estimated SF50 (the drug concentration used
following which 50% of cells survive) were calculated
using non-linear regression with GraphPad Prism V5.0.
Statistical analyses
Fisher’s exact tests using all collated mutation data
were used to determine association of co-occurrence
or mutual exclusivity between variables as previ-
ously described [27]. The Mann–Whitney U-test
and Student’s t-test were employed to compare
the mean expression of alternatively spliced exons
between SF3B1 wild-type and mutant tumours, and
between drug- and DMSO-treated cells. p values less
than 0.05 (two-sided) were considered statistically
significant.
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 235: 571–580
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Results
SF3B1 mutations are associated with ER-positive
breast cancer
A systematic re-analysis of exome and whole genome
sequencing data from TCGA and other published
studies [3–8] identified recurrent mutations in distinct
spliceosomal component genes previously reported
in other tumour types (Figure 1A, Table 1, and Sup-
plementary Table 6) [9,12,28,29]. Some mutations in
spliceosome genes appeared to be mutually exclusive,
including SF3B1 and PRPF8, and SF3B1 and SON
(odds ratio= 0, p< 0.05, Fisher’s exact test). Coin-
cident spliceosome mutations were also identified in
SF3B1 and LUC7L2, and in LUC7L2 and SAP130 in
two patients (Figure 1A). Although not significant,
mutations in LUC7L2 and SAP130 showed a trend
towards co-occurrence (odds ratio= 2.883, p= 0.9434,
Fisher’s exact test). Of the most common spliceosome
gene mutations (overall frequency> 0.5%), mutations
in SF3B1 were more common in ER-positive breast
cancer (2.2%, 21/936 ER-positive versus 0.3%, 1/289
ER-negative, p= 0.03914, Fisher’s exact test) and muta-
tions in SAP130 were more common in ER-negative
tumours (0.1%, 1/936 ER-positive versus 1.4%, 4/289
ER-negative, p= 0.012, Fisher’s exact test). Overall,
mutations in SF3B1 were the most common spliceo-
somal component gene mutation and were identified
in 1.8% of unselected breast cancers (23/1293), and
occurred as a recurrent hotspot T>C base-pair substitu-
tion at codon 700, leading to a glutamic acid from lysine
(K700E) in 74% (17/23) of mutant cases (Figure 1B
and Table 1). Additional recurrent mutations in SF3B1
occurred at codon 666 (K666Q and K666E) in 9% of
mutant tumours (2/23), and non-recurrent mutations
included G241*, N626D, A633V, Y765C, and D781E,
which were found in 22% (5/23; Supplementary Table
6). None of mutations were associated with loss of
heterozygosity of the wild-type allele (data not shown).
SF3B1 mutations are associated with specific
genomic alterations
A comparison of the genomic features of SF3B1 K700E
mutant tumours with available phenotypic information
(n= 16) with those of stage, ER, PR, HER2, PIK3CA,
and TP53 mutation status-matched SF3B1 K700E
wild-type tumours (n= 32; Supplementary Table 3)
revealed that SF3B1K700E mutant tumours displayed a
higher frequency of chromosomal gains on 16q12–q13
and 16q21–q22 and losses on 1p36–p35, 16q11–q13,
and 16q21–q23 (adjusted p< 0.05, multi-Fisher’s exact
test). These observations suggest that SF3B1 K700E
mutant tumours have a distinct repertoire of copy
number alterations (Supplementary Figure 1 and Sup-
plementary Table 7). No differences in the frequency
of amplifications between SF3B1 K700E mutant and
wild-type tumours were detected. Although no differ-
ence was seen in the total number of somatic coding
mutations between SF3B1 K700E mutant and wild-type
samples (p= 0.597, t-test; SF3B1 K700E mutant aver-
age 23.3, range 9–59; SF3B1 wild-type average 25.59,
range 1–85), 56.3% (9/16) of the SF3B1 mutant sam-
ples also carried PIK3CA mutations, while mutations in
TP53 were not as prevalent (6.3%, Figure 1C). In addi-
tion, AKT1 hotspot E17K mutations were found to be
significantly more frequent in SF3B1 K700E mutated
tumours (4/16) than in matched wild-type cancers
(0/32, p= 0.009353, Fisher’s exact test). Interestingly,
2 out of 24 (8.3%) mucinous carcinomas of the breast
annotated in the data were identified as having SF3B1
K700E mutations and lacked mutations in additional
significantly mutated genes or known cancer genes
(Figure 1C).
SF3B1 K700E mutations are more common
in ER-positive special histological types of breast
cancer
Given the apparent association of SF3B1mutations with
mucinous carcinomas of the breast, we screened addi-
tional cohorts of ER-positive special histological types
of breast cancer for SF3B1K700E mutations. Mucinous
(n= 18), papillary (n= 19), and micropapillary (n= 28)
carcinomas were subjected to Sanger sequencing (Sup-
plementary Table 1). K700E mutations were identified
in 6% (1/18), 16% (3/19), and 0% (0/28) of mucinous,
papillary, and micropapillary carcinomas, respectively.
These mutations were expressed at the RNA level in all
papillary carcinomas tested, where matched RNA was
available. Although the small number of cases subjected
to SF3B1 mutation profiling could have resulted in a
type I or α error resulting in a higher frequency of muta-
tions than the mutation rate in unselected breast cancers,
the probability of finding three samples harbouring an
SF3B1mutation by chance is less than 0.5% (based on a
binomial distribution assuming a mutation rate of 1.8%
in unselected breast cancers).
Given the higher frequency of SF3B1 K700E muta-
tions in papillary carcinomas of the breast, we hypothe-
sised that these mutations may underpin their biology
and may be present at additional hotspots and/or be
sub-clonal in the ‘wild-type’ samples. To address these
questions, the 19 papillary carcinomas were subjected to
targeted DNA re-sequencing of SF3B1 exons 14–16 and
of nine additional genes, which are recurrently mutated
in ER-positive breast cancers harbouring SF3B1 muta-
tions and have been postulated as drivers [5]. This anal-
ysis failed to identify additional or sub-clonal SF3B1
mutations in the 16 papillary carcinomas that had been
shown be SF3B1 wild-type by Sanger sequencing anal-
ysis. Overall, 63% (12/19) of the samples were found
to display mutations in additional cancer genes includ-
ing PIK3CA in 37% (7/19), TP53 in 5% (1/19), GATA3
in 11% (2/19), MAP3K1 11% (2/19), and MAP3K4 in
21% (4/19) (Figure 1D and Supplementary Table 8). In
contrast to SF3B1 mutant unselected breast cancers, no
papillary carcinomas in this series were found to harbour
AKT1 hotspot mutations.
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 235: 571–580
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
SF3B1 mutations in breast cancer 575
Figure 1. Repertoire of mutations in genes involved in mRNA splicing in breast cancer. (A) Summary of the mutations identified in genes
involved in mRNA splicing. Genes are listed on the right-hand side of the diagram and the breast cancer samples across the top. Mutations
show a mutually exclusive pattern indicating functional redundancy. Mutation data retrieved from TCGA plus published studies (Nik-Zainal
et al [3], Banerji et al [4], Ellis et al [5], TCGA [6], Shah et al [7], and Stephens et al [8]). (B) Distribution and frequency of SF3B1 mutations
derived from re-analysis of publicly available massively parallel sequencing data from the TCGA breast cancer study and additional
studies (as above). Note that mutations are clustered in the HEAT domain (exons 14–16) of the protein with a hotspot point mutation
at amino acid 700 (K700E). (C) Histological and molecular status of SF3B1 mutant samples from the re-analysis. Co-mutation analysis
shows PIK3CA missense mutations in 47.8% and AKT1 mutations in 17% of the samples, while mutations in other known driver genes
are present at lower frequencies. Note the lack of additional significantly mutated genes or known cancer genes in the two mucinous
carcinomas (curated from TCGA, http://www.cbioportal.org/public-portal/study.do?cancer_study_id=brca_tcga_pub, and the Cancer Gene
Census, https://cancer.sanger.ac.uk/cosmic). IC-NST= invasive carcinoma of no special type. (D) Repertoire of somatic mutations in 19
papillary carcinomas of the breast, as defined by targeted re-sequencing of known cancer genes. The genes are listed on the left-hand side
of the diagram and the breast cancer samples across the top. Two of the SF3B1 mutant tumours displayed additional mutations affecting
GATA3 and MAP3K4.
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 235: 571–580
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Table 1. Summary of spliceosome component mutational frequencies from the re-analysis of public sequencing data (n= 1293 tumours*)
Gene symbol No of cases with mutation Overall frequency (%) ER+ (%) ER−(%) HER2+ (%) TN(%)
SF3B1 23 1.8 2.1 0.3 1.8 0.5
PRPF8 8 0.6 0.6 0.7 0.9 0.5
SON 9 0.7 0.3 1.4 0.9 1.5
SAP130 6 0.5 0.1 1.4 0.9 0.5
LUC7L2 7 0.6 0.6 0.3 – 0.5
SF3B2 4 0.3 0.2 0.7 1.3 –
SRSF6 3 0.2 – 0.7 – 1.0
ZRSR2 2 0.2 – 0.7 – 0.5
U2AF2 2 0.2 0.1 0.3 0.4 0.5
SF3B4 2 0.2 0.1 0.3 0.4 –
SF3B3 2 0.2 0.1 0.3 0.4 0.5
SF1 2 0.2 0.1 0.3 – 0.5
PRPF40B 3 0.2 0.3 – – –
U2AF1L4 1 0.1 0.1 – – –
U2AF1 1 0.1 0.1 – – –
SRSF2 1 0.1 0.1 – 0.4 –
*Samples retrieved from Nik-Zainal et al [3], Banerji et al [4], Ellis et al [5], TCGA [6], Shah et al [7], and Stephens et al [8].
ER= oestrogen receptor; HER2+=HER2-positive; TN= triple-negative.
SF3B1 K700E mutations are associated
with differential splicing
Given the previous association of SF3B1 mutations
with differential splicing in uveal melanoma [13], we
hypothesised that SF3B1 K700E mutations in breast
cancer would also lead to differential splicing. Mas-
sively parallel RNA sequencing of SF3B1 mutant
(n= 3) versus wild-type (n= 11) papillary carcinomas
of the breast identified differential exon usage in 122
transcripts (p< 0.1 FDR, Supplementary Table 9). In
addition, re-analysis of available RNA-sequencing data
of (n= 8) SF3B1 K700E mutant and stage, ER, PR,
HER2, PIK3CA, and TP53 mutation status-matched
SF3B1 wild-type breast cancers (n= 16) from TCGA
revealed differential exon usage in 218 transcripts
(p< 0.1 FDR, Supplementary Table 10). Nine of these
genes were found to be in common, and seven showed
exact differential exon usage (TMEM14C, RPL31,
CRNDE, DYNLL1, ICA1, RPL24, and MTERFD3,
p= 2.988529e-14, hypergeometric test, Table 2). In
addition, four transcripts (ie TMEM14C, RPL31,
CRNDE, and DYNLL1) were found in common with
uveal melanoma [13] (p= 7.047575e-11, hypergeomet-
ric test) and these showed identical differential splicing
in papillary carcinomas of the breast, invasive breast
carcinomas of no special type, and uveal melanomas
displaying SF3B1 mutations (Figure 2 and Table 2).
We next additionally tested alternative splicing of
seven genes shown to be differentially spliced from
Furney et al [13] (GUSBP11, UQCC, ANKHD1, GAS8,
F8, ADAM12, and ABCC5) using qRT-PCR in SF3B1
mutant and wild-type papillary carcinomas. This analy-
sis identified UQCC, F8, ABCC5, and GUSBP11 to be
differentially spliced in papillary carcinomas, whereas
GAS8 and ADAM12 showed no difference (Supplemen-
tary Figure 2). Our results suggest that SF3B1mutations
are associated with alternative splicing of key genes
in ER-positive breast cancer that are independent of
tumour type.
Table 2. Alternative gene splicing associated with SF3B1
mutations in breast cancer
Gene
symbol Gene ID
This study
(DEXSeq)
TCGA
(DEXSeq)
Furney
et al [13]
Validated
qRT-PCR
TMEM14C ENSG00000111843 ✓ ✓ ✓ ✓
RPL31 ENSG00000071082 ✓ ✓ ✓ ✓
CRNDE ENSG00000245694 ✓ ✓ ✓ ✓
DYNLL1 ENSG00000088986 ✓ ✓ ✓ –
MZB1 ENSG00000170476 ✓ ✓ – –
ICA1 ENSG00000003147 ✓ ✓ – –
RPL24 ENSG00000114391 ✓ ✓ – –
MTERFD3 ENSG00000120832 ✓ ✓ – –
OBSL1 ENSG00000124006 ✓ ✓ – –
ABCC5 ENSG00000114770 – – ✓ ✓
UQCC ENSG00000101019 – – ✓ ✓
GUSBP11 ENSG00000228315 – – ✓ ✓
ANKHD1 ENSG00000131503 – – ✓ ✓
ADAM12 ENSG00000148848 – – ✓ ✓
F8 ENSG00000185010 – – ✓ NS
GAS8 ENSG00000141013 – – ✓ NS
NS= not significant (not validated).
SF3B1 mutant cells are sensitive to SF3b inhibition
Based on our observations that SF3B1 mutant tumours
display a conserved splicing signature, we posited that
differential splicing of the downstream targets may
drive tumour growth. Treatment of two SF3B1 mutant
cell lines, Panc 05.04 (pancreatic, K700E) and ESS-1
(endometrial, K666N), and six wild-type controls (three
pancreatic and three endometrial) with an SF3b complex
inhibitor, spliceostatin A, revealed that SF3B1 mutant
cell lines were significantly more sensitive to this agent
(p= 0.0118, t-test, Figure 3A). Moreover, treatment
with spliceostatin A resulted in significant perturbation
of the splicing signature, in a similar manner to SF3B1
siRNA-mediated knockdown (Figure 3C). In addition,
siRNA-mediated silencing of all transcripts of eight
genes that showed a consistent differential splicing sig-
nature across multiple cancer types (ABCC5, ANKHD1,
DYNLL1, F8, RPL31, TMEM14C,UQCC, andCRNDE)
failed to reveal differences in cell viability (Figure 3C).
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Figure 2. Identification of differential splicing in SF3B1 mutant (n= 3) and wild-type (n= 11) papillary carcinomas of the breast. Plots of
normalised RNA-sequencing reads for (A) CRNDE , (B) TMEM14C , and (C) RPL31 in SF3B1 wild-type (blue) and SF3B1 mutant (red) tumours.
Schematic representations of the exon structures are shown above the graph, with exons represented by boxes. Differentially spliced exon
bins are indicated by lighter coloured shading. Box plots representing the validation of the differential splicing event in wild-type (blue)
versus mutant (red) tumours by quantitative RT-PCR.
In addition, silencing of specific splice variants of
CRNDE failed to identify any SF3B1 mutant-specific
effects (Figures 3D and 3E). These results suggest that
SF3B1mutations are likely driving themalignant pheno-
type of the cells through perturbations in RNA splicing;
however, this driving effect could not be ascribed to a
single differentially spliced transcript tested.
Taken together, our findings demonstrate that
although SF3B1 mutations are unlikely to account for
the histological characteristics of papillary carcinomas
of the breast, these mutations affect mRNA splicing and
likely constitute driver genetic events.
Discussion
Here we describe the repertoire of mutations in spliceo-
somal components in breast cancer through a re-analysis
of public exome and whole genome sequencing data.
Our data reveal that some spliceosome mutations are
mutually exclusive in breast cancer, consistent with the
observations made in myelodysplastic lesions [9]; how-
ever, a small proportion of tumours harboured mutations
in more than one spliceosome component. Moreover,
we demonstrate that SF3B1 is the most commonly
mutated spliceosomal component gene in breast cancer
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Figure 3. SF3B1mutant cells are sensitive to SF3b inhibition. (A) Dose–response curves of SF3B1mutant cancer cell lines (red) or wild-type
(blue) to the SF3b complex inhibitor spliceostatin A (p= 0.0118, t-test). (B) Bar plots of the relative expression of alternative spliced
transcripts in ESS-1 cells upon 12 h spliceostatin A (SSA) treatment (SF30 concentration) or SF3B1 siRNA-mediated silencing relative
to vehicle (DMSO) or non-targeting controls (siCON). Error bars represent the standard error of the mean of three replicates. (C) Bar
plots illustrating the normalised percentage inhibition (NPI) relative to siCON negative and ubiquitin B positive controls of cells following
transfection with SMARTpool siRNA of ABCC5, ANKHD1, DYNLL1, F8, RPL31, TMEM14C , UQCC , and CRNDE in SF3B1 mutant (red) or
wild-type (blue) cancer cells. Error bars represent the standard error of the mean of three replicates. None of the genes showed a significant
difference in cell viability between mutant and wild-type cells (p> 0.05, t-test). (D) Bar plots illustrating the normalised percentage
inhibition (NPI) relative to siCON negative and ubiquitin B positive controls of cells following transfection with custom siRNA oligos against
the CRNDE alternative spliced isoform (eb6) in SF3B1 mutant (red) or wild-type (blue) cancer cells. Error bars represent the standard error
of the mean of three replicates. None of the genes showed a significant difference in cell viability between mutant and wild-type cells
(p> 0.05, t-test). (E) Bar plot showing qPCR validation of siRNA oligos against the CRNDE alterative spliced isoform (eb6) relative to siCON.
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and that mutations affecting this gene are significantly
associated with ER-positive disease. In addition, SF3B1
mutations are found to be associated with specific
genomic alterations including concurrent AKT1 hotspot
mutations and a lower frequency of the hallmark chro-
mosomal aberrations reported in ER-positive IC-NST
(ie loss of 16q) akin to mucinous carcinomas of the
breast [23]. Our exploratory, hypothesis-generating
analysis of special histological types of breast cancer
provides evidence to suggest that the codon 700 SF3B1
hotspot mutations may be more prevalent in mucinous
and papillary carcinomas of the breast than in usual
types of breast cancer of the same grade, ER, and HER2
status. Targeted re-sequencing of our cohort of 19
papillary carcinomas of the breast failed to identify any
sub-clonal mutations in additional tumours, indicating
that these mutations, when present, are found in the
modal clone of the lesions, but are unlikely to account
for the papillary histological pattern.
The SF3B1 gene encodes subunit 1 of splicing fac-
tor 3b, a component of the U2 small nuclear ribonu-
cleoprotein, which is involved in catalysing precursor
mRNA to mature transcripts. SF3B1 contains several
HEAT domains (Huntingtin, Elongation factor 3, protein
phosphatase 2A, Target of rapamycin 1), which are the
hotspots for the majority of the somatic mutations previ-
ously documented [10,13,15]. Studies have highlighted
that primary tumours with SF3B1 mutations display
alternative splicing in selected key genes in CLL [12],
MDS [30], and uveal melanoma [13], and that this sig-
nature is conserved between cancer sites and is indepen-
dent of the mutant amino acid [16]. Using a combination
of RNA sequencing and qRT-PCR, we identified eight
differentially spliced transcripts between mutant SF3B1
and wild-type breast cancers that were also reported to
be differentially spliced in SF3B1 mutant melanomas
[13], highlighting that this signature is additionally con-
served in breast cancer.
Given that the spliceosome SF3b complex has
emerged as a potential therapeutic target [31], we
sought to define whether cancer models harbouring
SF3B1 hotspot mutations would be sensitive to chemical
inhibition of SF3B1and RNA-interference silencing of
SF3B1 and genes abnormally spliced in SF3B1 mutant
tumours [32]. Here we demonstrate that treatment of
SF3B1mutant and wild-type cell lines with spliceostatin
A resulted in selective inhibition of the growth of mutant
cells and in the disruption of the conserved splicing
signature. Interestingly, single gene RNAi-mediated
silencing of key differentially spliced genes had no
effect on cell viability. Although it is plausible that the
differentially spliced genes investigated in this study did
not account for the dependency of SF3B1 mutant cells
on aberrant splicing, it is conceivable that the differences
in pre-mRNA splicing act in concert to produce a cell
survival advantage. Given the difficulties in silencing
multiple genes systematically, this remains to be tested.
In conclusion, our findings demonstrate that spliceo-
somal mutations occur in a mutually exclusive manner
in breast cancer and that distinct components of the
spliceosome are targeted by somatic mutations in dif-
ferent types of breast cancer (eg SF3B1 and SAP130
were found to be preferentially mutated in ER-positive
and ER-negative disease, respectively). We have
demonstrated that SF3B1 K700E mutations are more
frequently found in some special histological types
of breast cancer and have provided direct evidence
that these are associated with consistent differential
splicing patterns in breast cancer. Finally, our study
emphasizes the importance of driver genetic alterations
found in minor subgroups of breast cancer, given
that SF3B1 mutant cells were shown to be selectively
sensitive to a potent SF3b complex inhibitor, spliceo-
statin A, suggesting that inhibition of the spliceosome
complex may constitute a novel therapeutic strategy
for patients with SF3B1 mutations independent of
tumour type.
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